newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

BIAFBIAFW
  • bioAffinity Technologies, Inc. announced a pilot study with Brooke Army Medical Center to evaluate proprietary flow cytometry+AI diagnostic tests for asthma and COPD.
  • The study aims to identify inflammatory biomarkers in sputum to align patients with effective treatments and monitor drug efficacy over time.
  • Approximately 40 participants will be enrolled in three cohorts: patients with asthma, patients with COPD, and a healthy control group.
  • Research focuses on the military context where asthma often presents differently due to environmental and deployment-related hazards compared to civilian populations.
  • The collaboration leverages bioAffinity's technology to assess lung inflammation at the cellular level, supporting a precision medicine approach.
  • The study objective is to determine if flow cytometry and ELISA analysis can help tailor treatment strategies for service members and veterans.
  • bioAffinity's existing CyPath® Lung test demonstrated 92% sensitivity and 99% negative predictive value in detecting lung cancer in high-risk patients during clinical trials.
  • The asthma and COPD treatment market targeted by this research is estimated at $92 billion.
  • CyPath® Lung is marketed as a Laboratory Developed Test (LDT) under CLIA regulations and is not intended as a sole diagnostic tool.
  • Forward-looking statements in the release are subject to risks including study results, regulatory status, and enrollment capabilities.